I was happy to be able to attend the virtual SGO Annual Meeting. The meeting started on Friday, March 19 with sessions during the day and evenings over the weekend. The meeting continues with evening sessions through Thursday March 25th. Interacting with presenters and others in the chat feature of the meeting platform was exceptionally good and helpful.
In real time, I shared information on Twitter( @womenofteal) about the sessions I attended using the #gyncsm and #SGOmtg hashtags. Below are some tweets of Fridays sessions I found most interesting.
Now Watching: Catching Up to Speed on the Role of Nutritional Supplements in the Management of Gynecologic Cancer Patients w/ Dr Smith #SGOMtg #SGOPatAdv #GYNcsm— Dee Sparacio (@womenofteal) March 19, 2021
Patient use of supplement has increased up to 60%. Wealth of info like below. pic.twitter.com/OM17J62Q01
Patients: Please talk to your medical team ASAP if you are currently on treatment & taking any of these supplements! #SGOmtg session: Catching Up to Speed on the Role of Nutritional Supplements in the Management of Gynecologic Cancer Patients w/J Smith PharmD #SGOPatAdv #GYNcsm pic.twitter.com/fHW2HP8BtV— Annie Ellis (@Stigetta) March 19, 2021
Patient physician conversations
#sgomtg Navigating High Stakes Conversations in Gynecologic Oncology great discussion on those difficult discussions using VITALtalk Excellent consideration of patient goals and needs. #gyncsm pic.twitter.com/GHfNnXrXkR— Dee Sparacio (@womenofteal) March 19, 2021
Listening to PARP Inhibitors: A Practical Approach to Selection and Management :— Dee Sparacio (@womenofteal) March 19, 2021
Karen Lyle, PA-C , Colleen McCormick, MD, MPH
Excellent overview of trial results of PARP use and its current approval for use.
#SgoMtg #gyncsm pic.twitter.com/Ph1IOS13Js
ARIEL 4 Rucaparib vs chemo
KEYNOTE 146 Pembrolizumab - Lenvatinib
Additional information may be found in the ASCO Post Article https://ascopost.com/news/march-2021/pembrolizumablenvatinib-may-improve-survival-in-advanced-endometrial-cancer/?utm_source=TAP%2DEN%2D032021&utm_medium=email&utm_term=51c356fa5771cf054b74a66e437b4089
Secondary Cytoreductive Surgery
Dr. Arend presents exciting data of a DKK1 inhibitor (DKN-01) in #endometrialcancer - biomarker selection seems possible using DKK1 expression, WNT mutation or PIK3CA mutation. Will be exciting to see this move forward! #SGOMtg #gyncsm pic.twitter.com/nz9yDpKyNp— Shannon Westin (@ShannonWestin) March 19, 2021
Equity in Gyn Cancers
ACA and insurance
>1/5 with #gynecologicalcancer #gyncsm have insurance churn, losing/changing #healthinsurance causing dangerous access/coverage gaps. Catastrophic spending in common. Static assessment of insurance gives us an incomplete picture. Great work @BenAlbrightMD @haleyarden1 👏 @SGO_org https://t.co/wLZEFe6EcV— Fumiko Ladd Chino, MD (@fumikochino) March 21, 2021
Here was a fun activity on the meeting platform - puzzle time! How I wish we were actually in Seattle
Every Day is a Blessing!